Sarepta Therapeutics' (SRPT) Sell Rating Reaffirmed at HC Wainwright

Key Points

• Sarepta Therapeutics' stock has been restated with a "sell" rating by HC Wainwright, amid various other rating changes from different analysts.
• The company's quarterly earnings showed a significant loss of ($3.42) per share, missing estimates, despite a 80.2% revenue increase compared to the previous year.
• Currently, the average analyst rating on Sarepta Therapeutics is "Hold" with a price target averaging $49.88, reflecting cautious sentiment among market analysts.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "sell" rating reissued by stock analysts at HC Wainwright in a note issued to investors on Tuesday, Marketbeat reports.

Other analysts have also issued research reports about the company. Mizuho restated a "neutral" rating and issued a $14.00 price objective (down previously from $40.00) on shares of Sarepta Therapeutics in a research note on Monday, July 21st. Royal Bank Of Canada decreased their target price on Sarepta Therapeutics from $25.00 to $23.00 and set a "sector perform" rating on the stock in a report on Thursday, July 17th. Citigroup started coverage on shares of Sarepta Therapeutics in a research report on Tuesday, July 22nd. They set a "sell" rating for the company. Evercore ISI downgraded shares of Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 price objective on the stock. in a report on Thursday, May 8th. Finally, JPMorgan Chase & Co. raised shares of Sarepta Therapeutics from an "underweight" rating to a "neutral" rating and set a $24.00 target price for the company in a report on Tuesday. Six equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $49.12.

Sarepta Therapeutics Stock Down 3.1%

SRPT traded down $0.51 on Tuesday, hitting $15.91. 9,339,167 shares of the company were exchanged, compared to its average volume of 5,775,559. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.46 and a current ratio of 4.02. The stock's fifty day moving average is $24.24 and its 200-day moving average is $61.50. The company has a market cap of $1.56 billion, a PE ratio of -5.91 and a beta of 0.45. Sarepta Therapeutics has a 12 month low of $10.41 and a 12 month high of $145.00.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The company had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. During the same period in the previous year, the company posted $0.73 EPS. The company's quarterly revenue was up 80.2% compared to the same quarter last year. Equities research analysts predict that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SRPT. Byrne Asset Management LLC bought a new stake in shares of Sarepta Therapeutics in the 1st quarter valued at about $30,000. Center for Financial Planning Inc. bought a new position in Sarepta Therapeutics in the first quarter worth approximately $31,000. Logan Capital Management Inc. purchased a new stake in Sarepta Therapeutics during the fourth quarter worth $61,000. Ancora Advisors LLC boosted its position in Sarepta Therapeutics by 150.0% during the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 300 shares in the last quarter. Finally, Hurley Capital LLC purchased a new position in shares of Sarepta Therapeutics in the 4th quarter valued at $76,000. 86.68% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.